Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Sponsor: Methodist Health System
Summary
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Official title: Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
35
Start Date
2023-08-03
Completion Date
2026-07-09
Last Updated
2026-08-04
Healthy Volunteers
No
Conditions
Interventions
PSMA radionuclide therapy
Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
Locations (1)
Methodist Dallas Medical Center
Dallas, Texas, United States